|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Celgene International Sárl (CELG) Release: Premiere Cooperative Group in Adult Lymphoma Research (GELA) Chooses REVLIMID® for Study in Second Most Common Lymphoma Subtype
12/14/2011 6:28:34 AM
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (Nasdaq: CELG) and the Groupe d’Etude des Lymphomes de l’Adulte (GELA) today announced the organizations have initiated an international, Phase III, open-label, randomized study to evaluate the therapeutic potential of a novel chemotherapy-free approach for the treatment of follicular lymphoma (FL). The combination of REVLIMID (lenalidomide) and rituximab, also referred to as the R-squared (or R2) regimen pioneered by Nathan Fowler, MD and colleagues at the MD Anderson Cancer Center, Houston TX, will be investigated in a study of up to 1,000 patients with newly diagnosed FL. GELA is considered a leading cooperative group for studying the treatment of adult lymphoma patients, and its work has helped establish the standard of care in the treatment of FL as well as other lymphomas.
|
|
|
|
|
|
|
|
|
|
|